TNFRSF9 and neoplasm: The 4-1BB-binding domain may drive the aggregation of 4-1BB molecules on the surface of T cells, so that 4-1BB-mediated immune activation can be concentrated on T cells near the tumor, effectively reducing the potential off-target toxicity.